Gregory D. Davis - 24 Feb 2026 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Signature
/s/ Scott Willoughby, Attorney-in-Fact
Issuer symbol
SGMO
Transactions as of
24 Feb 2026
Net transactions value
-$2,799
Form type
4
Filing time
26 Feb 2026, 21:40:07 UTC
Previous filing
26 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davis Gregory D Head of Research & Technology C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND /s/ Scott Willoughby, Attorney-in-Fact 26 Feb 2026 0002041855

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Tax liability $393 -832 -0.44% $0.4725 190,230 24 Feb 2026 Direct F1, F2
transaction SGMO Common Stock Tax liability $2,406 -5,119 -2.7% $0.4700 185,111 25 Feb 2026 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2 Includes: (a) 1,190 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F3 Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F4 Includes: 7,313 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 37,294 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.